163 related articles for article (PubMed ID: 10321518)
1. Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Shephard SE; Nestle FO; Panizzon R
Photodermatol Photoimmunol Photomed; 1999 Apr; 15(2):64-74. PubMed ID: 10321518
[TBL] [Abstract][Full Text] [Related]
2. Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):258-65. PubMed ID: 9885410
[TBL] [Abstract][Full Text] [Related]
3. Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Balogh A; Merkel U; Looks A; Vollandt R; Wollina U
Exp Toxicol Pathol; 1998 Sep; 50(4-6):397-401. PubMed ID: 9784014
[TBL] [Abstract][Full Text] [Related]
4. Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
Holien T; Gederaas OA; Darvekar SR; Christensen E; Peng Q
Lasers Surg Med; 2018 Jul; 50(5):469-475. PubMed ID: 29460964
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induction by extracorporeal photopheresis is enhanced by increasing the 8-methoxypsoralen concentration and by replacing plasma with saline.
Hähnel V; Brosig AM; Ehrenschwender M; Burkhardt R; Offner R; Ahrens N
Transfusion; 2021 Oct; 61(10):2991-2999. PubMed ID: 34427336
[TBL] [Abstract][Full Text] [Related]
6. [Documented effect of extra corporeal photopheresis on T-cell mediated diseases].
Kofoed K; Schiødt I; Gniadecki R
Ugeskr Laeger; 2011 Jun; 173(26):1869-74. PubMed ID: 21712008
[TBL] [Abstract][Full Text] [Related]
7. A method for the quantification of 8-methoxypsoralen by mass spectrometry for offline extracorporeal photopheresis.
Hähnel V; Dormann F; Nitsopoulos A; Friedle A; Ahrens N
Photochem Photobiol Sci; 2017 Feb; 16(2):193-200. PubMed ID: 27976780
[TBL] [Abstract][Full Text] [Related]
8. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of 8-methoxypsoralen during extracorporeal photochemotherapy: evidence for a "first-dose" effect.
Jacolot A; Tod M; Heudes AM; Petitjean O; Laroche L
Ther Drug Monit; 1996 Jun; 18(3):234-9. PubMed ID: 8738761
[TBL] [Abstract][Full Text] [Related]
10. Matrix-dependent absorption of 8-methoxypsoralen in extracorporeal photopheresis.
Hähnel V; Weber I; Tuemmler S; Graf B; Gruber M; Burkhardt R; Ahrens N
Photochem Photobiol Sci; 2020 Aug; 19(8):1099-1103. PubMed ID: 32638713
[TBL] [Abstract][Full Text] [Related]
11. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
12. High plasma levels of 8-methoxypsoralen following bath water delivery in dermatological patients.
Kappes UP; Barta U; Merkel U; Balogh A; Elsner P
Skin Pharmacol Appl Skin Physiol; 2003; 16(5):305-12. PubMed ID: 12907835
[TBL] [Abstract][Full Text] [Related]
13. An alternative for extracorporeal photopheresis: 8-methoxypsoralen and UVA-treated leucocytes from allogeneic donors improve graft-versus-host disease in mice.
Budde H; Papert S; Reichardt HM; Jarry H; Riggert J; Legler TJ
Vox Sang; 2018 Nov; 113(8):803-810. PubMed ID: 30353554
[TBL] [Abstract][Full Text] [Related]
14. The North American experience with photopheresis.
Zic JA; Miller JL; Stricklin GP; King LE
Ther Apher; 1999 Feb; 3(1):50-62. PubMed ID: 10079806
[TBL] [Abstract][Full Text] [Related]
15. Mini buffy coat photopheresis for children and critically ill patients with extracorporeal photopheresis contraindications.
Hackstein H; Misterek J; Nockher A; Reiter A; Bein G; Woessmann W
Transfusion; 2009 Nov; 49(11):2366-73. PubMed ID: 19903292
[TBL] [Abstract][Full Text] [Related]
16. Parenteral administration of 8-methoxypsoralen in photopheresis.
Knobler RM; Trautinger F; Graninger W; Macheiner W; Gruenwald C; Neumann R; Ramer W
J Am Acad Dermatol; 1993 Apr; 28(4):580-4. PubMed ID: 8463458
[TBL] [Abstract][Full Text] [Related]
17. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
[TBL] [Abstract][Full Text] [Related]
18. A standardized methodical approach to characterize the influence of key parameters on the in vitro efficacy of extracorporeal photopheresis.
Laulhé M; Lefebvre S; Le Broc-Ryckewaert D; Pierre M; Ferry A; Delorme B
PLoS One; 2019; 14(3):e0212835. PubMed ID: 30822323
[TBL] [Abstract][Full Text] [Related]
19. The lack of efficacy of 4,6,6'-trimethylangelicin to induce immune suppression in an animal model for photopheresis: a comparison with 8-MOP.
van Iperen HP; Brun BM; Caffieri S; Dall'Acqua F; Gasparro FP; Beijersbergen Henegouwen GM
Photochem Photobiol; 1996 May; 63(5):577-82. PubMed ID: 8628748
[TBL] [Abstract][Full Text] [Related]
20. Retinal toxic reactions following photopheresis.
Vagace JM; Gervasini G; Morais F; Benitez J; Alonso N; de Argila D; Arranz I; Bajo R
Arch Dermatol; 2007 May; 143(5):622-5. PubMed ID: 17515512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
